"We have made good progress with dose escalation in this study and are encouraged by the safety and tolerability profile to date and by the attainment of therapeutic factor VIII activity levels in the first patient in the third dose cohort," Edward Conner, MD, chief medical officer of Sangamo, said in a press release.